We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Antifibrotic Therapy
MedXY News
EnglishTag

Antifibrotic Therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseaseepidemiologybreast cancer

Latest news

Tag

Impact of Antifibrotic Dose Modifications on Idiopathic Pulmonary Fibrosis Outcomes: Insights from Real-World Data
newsAntifibrotic Therapyclinical outcomes

Impact of Antifibrotic Dose Modifications on Idiopathic Pulmonary Fibrosis Outcomes: Insights from Real-World Data

By MedXY|Oct 9, 2026

This study investigates how dose reductions and discontinuations of antifibrotic therapies influence disease progression in idiopathic pulmonary fibrosis (IPF), revealing significant challenges in drug tolerability and the need for improved

Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model
newspirfenidone
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Glottic Stenosis

Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model

By MedXY|Sep 17, 2026

This study investigates the efficacy of topical and systemic pirfenidone in reducing glottic stenosis induced by bleomycin in rats, demonstrating both routes reduce macroscopic stenosis, with systemic administration showing significant anti

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial
newsAntifibrotic Therapypirfenidone

Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial

By MedXY|Nov 12, 2025

A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
Clinical UpdatesAntifibrotic TherapyBexotegrast

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY|Sep 17, 2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models